Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert Martin Emanuele is Director at Artelo Biosciences. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jul 21, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
Artelo BiosciencesARTL
2 disclosures · Feb 2026 – Jul 2026
Jul 17, 2026136disclosed Jul 21
DetailsOfficial recordJan 30, 2026292disclosed Feb 2
DetailsOfficial recordRobert Martin Emanuele has no open-market purchase on record since 2011. Sales in 1 of the 16 years since 2011.
Robert Martin Emanuele reported 0 open-market purchases and 1 sale since 2011; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2011 | — | $25K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Robert Martin Emanuele has no open-market purchase on record since 2011. Sales in 1 of the 16 years since 2011.
In SEC filings since 2011: no open-market purchase is on record; the latest open-market sale is from 2011.
Savara (SVRA), from 2011 to 2011: 0 purchases and 1 sale.
Robert Martin Emanuele reported 0 open-market purchases and 1 sale here, 2011.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.